NIOX Group (LSE:NIOX) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:NIOX NIOX Group PLC LSE:NIOX
50 GF Score
Price £0.57
GF Value £0.87
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is NIOX Group FFO?

FFO (Funds from operations) only applies to REITs.

LSE:NIOX
50GF Score
NIOX Group PLC LSE:NIOX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NIOX Group (LSE:NIOX) Overvalued in 2026?

Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued. The current stock price of £0.57 is trading 34.3% below its estimated GF Value™ of £0.87. GuruFocus considers NIOX Group to be Significantly Undervalued.

Key valuation signals for LSE:NIOX:

  • FFO:
  • GF Value™: £0.87 vs. price of £0.57 (34.3% below fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the LSE:NIOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NIOX Group Business Description

Address 1 Robert Robinson Avenue, Magdalen Centre, The Oxford Science Park, Oxford, GBR, OX4 4GA
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
50GF Score

Get the complete analysis for LSE:NIOX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.57
Price
£0.87
GF Value